2025
article
OpenAlex
Javier A. Pagan, Tali Elfassy, Miguel Antonio Bandes, Nicolas Sarmiento Bustamante et autres
Purpose The proportion of lupus patients with end-stage kidney disease (ESKD) undergoing preemptive kidney transplantation (PKT) is <5%, due to concern for poor outcomes. In this study, we estimate trends and the likelihood of PKT in lupus patients compared to non-lupus patients …
us, cr
(code pays fourni par la source)
2024
article
OpenAlex
Gabriel Contreras, Javier A. Pagan, Tali Elfassy, Miguel Antonio Bandes et autres
Background: The proportion of patients with lupus approaching end-stage kidney disease (ESKD) and undergoing preemptive kidney transplantation (PKT) is <5%, due to concern for poor outcomes. In this study, we describe PKT trends in lupus versus non-lupus patients from 1985 to 2019. …
us, cr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Taha Qarni, Felipe J.S. Jones, Brian Drachman, Sami Khella et autres
BACKGROUND: There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Gabriel Nicolas Contreras Martin, Javier A. Pagan, Nicolas Sarmiento Bustamante, Mariella Ortigosa‐Goggins et autres
Preemptive kidney transplantation improves survival of patients approaching end-stage renal disease (ESRD); however, on average only 2.3% of incident ESRD patients undergo preemptive kidney transplantation. In this longitudinal study, we compare trends of preemptive kidney transplantation in ESRD patients, stratifying by their …
us, cr
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Taha Qarni, Felipe J.S. Jones, Brian Drachman, Sami Khella et autres
us
(code pays fourni par la source)
2023
article
OpenAlex
Nicolas Sarmiento Bustamante, Taha Qarni, Felipe Simoes Jones, Sami Khella et autres
Objective: To describe patients’ characteristics of a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the Penn Amyloidosis Center between 2018 and 2022. Background: The characteristics of hATTR patients and their prognosis varies greatly depending on the type of …
us, kr
(code pays fourni par la source)
2023
article
OpenAlex
Taha Qarni, Nicolas Sarmiento Bustamante, Felipe Simoes Jones, Sami Khella et autres
Objective: We aimed to describe and compare treatment modalities in a large cohort of patients with hereditary transthyretin amyloidosis (hATTR) seen at the University of Pennsylvania Amyloidosis Center. Background: Treatments for hATTR amyloidosis fall into 2 major categories: transthyretin (TTR) stabilizers (tafamidis …
us, kr
(code pays fourni par la source)